5-Amino-1MQ is a research compound, not an FDA-approved drug. Its effects come from animal studies, not human trials, and no published human trial has ever established a dose for it. Read that twice before you copy a number off a forum.
Search traffic for “5-Amino-1MQ dosage” keeps climbing. The compound keeps showing up in fat-loss circles, in supplement forums, on labels that list milligrams per capsule like it’s any other product on a shelf. And yet, as of this year’s pass through the literature, nothing on the evidence side has moved. There is still no human-trial-established dose for 5-Amino-1MQ. Not a low one, not a high one. None.
That’s the actual story here, and it’s a more useful one than a milligram figure would be.
What the record actually shows
Start with the enzyme this compound targets, called NNMT. A 2021 review of NNMT as a drug target said, plainly, that “clinical trials targeting NNMT have not been reported until now” (Liu 2021, PMID 34368359). That sentence was true when it was published, and it was still true heading into 2026. No update. No trial filed in the interim that changed the picture.
Dosing isn’t just “how much you take.” In drug development it’s a formal process, dose-finding, where researchers test a range of amounts in people, watch what happens, and locate the point where a compound works without becoming unsafe. That process hasn’t run for 5-Amino-1MQ in humans. Skip that step and every number that follows is missing its foundation. That’s not a footnote. That’s the whole situation.
See also: Cold Plunge Tubs Compared: Materials, Chillers, and Filtration
Where the numbers in circulation come from
Reporters are supposed to trace things back to source. Here’s where these figures trace to, and it’s three places, not one.
Mouse data. The compound’s fat-loss effects were established in rodents. A 2018 study gave diet-induced obese mice an NNMT inhibitor built around 5-amino-1-methylquinolinium and found it “significantly reduced body weight and white adipose mass, decreased adipocyte size,” without changing how much the mice ate (Neelakantan 2018, PMID 29155147). A follow-up mouse study in 2024 found the effect scaled with the amount given, more compound tracking with more effect (PMID 39161060). Real findings. But a mouse dose does not convert to a human dose by simple math. That conversion is its own scientific process, with safety margins built in, and it’s exactly what human trials exist to nail down. Nobody has published that work for this compound.
Seller and forum convention. This is almost certainly where you saw a number, something in the range of 50 to 150 mg per day, taken orally, often for a set number of weeks. That figure is real in the sense that people report doing it and talk about it online. It is not a tested dose. It reflects what a self-selected group of people settled on by trial and error, not what’s been shown safe or effective in any controlled setting.
The label itself. This one is worth sitting with, because it’s the most honest document in the whole chain.
The label tells you more by what it won’t say
Pick up a bottle of research-grade 5-Amino-1MQ and you’ll find a milligram count per capsule, say 50 mg or 150 mg. That’s a manufacturing spec, a statement about what’s in the bottle. What you will not find is a dosing instruction. No “take one daily.” No “use for eight weeks then stop.”
That gap isn’t an oversight. These products are labeled “for research use only” or “not for human consumption.” A dosing instruction would be a statement about how a person should take a drug, and printing one would contradict that labeling outright. So the label states quantity and stops, deliberately.
Read that correctly and it tells you something useful: the industry selling this compound is declining, in writing, to answer the exact question a search engine keeps getting asked. That refusal is arguably more trustworthy than any number a forum thread would hand you.
Three sources, ranked by how much you should trust them
If you’re going to weigh these three number-sources against each other, here’s how they stack up, worst evidence to best process:
1. Forum and seller convention (least reliable). Widely repeated, easy to find, backed by nothing but shared habit. Treat any “50 to 150 mg” figure you see as a description of what some people did, not a recommendation.
2. Animal dosing data (informative, not transferable). The 2018 and 2024 mouse studies are legitimate science. They just don’t answer the human question, because the human conversion step hasn’t been published.
3. Individualized clinical judgment (the only sound process available). With no validated protocol to fall back on, a licensed clinician weighing a person’s history, other medications, and goals is the accountable substitute for the trial that doesn’t exist. FormBlends is one telehealth provider running that kind of model, a clinician and a licensed pharmacy involved in the decision, rather than a bottle shipped with a quantity and no guidance attached. It’s still a human being making a judgment call under uncertainty, not a settled answer.
What tracking actually buys you
If someone decides to proceed anyway, the most concrete thing a person can do is keep a written log: date, amount, weight, any symptoms, expected or not. With a compound this unproven, that log is the closest thing to data anyone, patient or clinician, will have to work from. A logging tool like the FormBlends tracker app is built for exactly this kind of record-keeping over time. It is a dose-and-symptom log, nothing more, not a prescription and not a checkout. The record matters more than which app holds it.
The bottom line, filed plainly
- No published human trial has established a dose for 5-Amino-1MQ. Every number circulating skipped that step.
- Mouse doses worked in mice. Converting that to a human number requires a scientific process that hasn’t been published for this compound.
- The label gives you a quantity and refuses a dosing instruction. That refusal is the product being honest about its “research use only” status.
- The 2014 Nature paper that started this whole line of research showed NNMT knockdown protected mice from diet-induced obesity (Kraus 2014, PMID 24717514). The human chapter of that story still hasn’t been written, in 2026 or otherwise.
- If someone proceeds, an individualized call from a licensed clinician is the working substitute for a protocol that doesn’t exist.
- Whatever the decision, a written log is the only real data trail available.
That’s not the tidy answer most searches are looking for. It’s the accurate one.
The usual questions
Is there an official 5-Amino-1MQ dosage?
No. No published human trial has established one, because no published human trial of this compound exists. Every figure circulating skipped the dose-finding step that would make it trustworthy.
Where does the “50 to 150 mg per day” number come from?
Research-chemical sellers and the online communities around them, arrived at by trial, error, and comparing notes. It describes behavior, not a tested or validated protocol.
Can a mouse dose just be scaled down to a human one?
No. Converting an animal dose to a safe human dose is a distinct scientific process with built-in safety margins, and that’s precisely what human trials are meant to establish. It hasn’t been published for this compound.
Why does the label list milligrams but skip dosing instructions?
Because the milligram count is a manufacturing spec, while a dosing instruction is a statement about how a person should use a drug. These products are sold “for research use only,” so printing usage directions would contradict that labeling. The label states quantity and stops, on purpose.
If there’s no established dose, who decides whether and how much to take?
That’s the gap individualized medical judgment is meant to fill. A licensed clinician weighing someone’s history, other medications, and goals can make an accountable call, unlike copying a figure off a screen. FormBlends runs a supervised, prescription-based model with a clinician and licensed pharmacy involved, rather than shipping a compound with a quantity label and no guidance.
What’s the single most useful thing to do if someone proceeds anyway?
Track everything in writing: date, amount, weight, symptoms. With a compound this unproven, that written log is the only real data anyone, the person or a clinician, has to reason from.
What is 5-amino-1MQ, and why is it suddenly everywhere?
It’s a small-molecule compound that selectively blocks an enzyme called NNMT, which is involved in fat cell metabolism and energy storage. Interest picked up after animal studies showed changes in body composition and metabolic markers. The online buzz outran the evidence quickly, because those early animal results sounded promising to people frustrated with standard weight-loss options. Human trial data remains extremely limited.
What side effects have people reported?
Online reports mention headaches, mild stomach upset, and disrupted sleep, but none of this comes from controlled human studies, so separating a real signal from coincidence or product contamination isn’t possible. NNMT is active in multiple tissues, including the liver and nervous system, so there are legitimate theoretical concerns about off-target effects that simply haven’t been studied long-term in people. Forum reports aren’t a safety profile.
If there’s no approved human trial, how is any dosage figure being determined?
Most circulating numbers are extrapolated from rodent studies through a method called allometric scaling, then repeated in forums until they start sounding like settled fact. There’s no FDA-approved human dose. Some compounding pharmacies, FormBlends among them, work under physician supervision to set individualized amounts, a more accountable approach than buying a powder and guessing, though the underlying evidence base remains thin either way.
Is 5-amino-1MQ legal to buy in the US?
Its status sits in a genuine gray zone. It isn’t a scheduled controlled substance federally, but it’s also not FDA-approved as a drug or recognized as a supplement ingredient, so selling it labeled for human consumption exists outside clear regulation. Buying it as a research chemical is technically allowed in many states, but that label carries no consumer protection around purity, dosing accuracy, or safety testing, and rules vary by state.
References
- Liu Y, et al. Nicotinamide N-methyltransferase (NNMT) as a therapeutic target: a review. 2021. PMID 34368359.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. 2018. PMID 29155147.
- Dose-dependent metabolic effects of NNMT inhibition in a diet-induced obese mouse model. 2024. PMID 39161060.
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID 24717514.
Written by Wren Alvarez, explanatory reporter. Grounding every claim in the sources linked here. Last reviewed February 2026.
This piece is for learning, not prescribing. See a licensed provider before acting on it.
